supp.fit

Curcumin and Turmeric: study protocols

6 study groups took Curcumin together with Turmeric. These are the doses the studies gave. They are not a recommendation.

Curcumin: what the research found →

Dose per serving from research: Curcumin

6 study groups in 5 studies say how much Curcumin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 50% of 6 study groups.

Daily doseStudy groups
50 mg to 100 mg
3
100 mg to 250 mg
1
250 mg to 500 mg
2

Commonly used together

None of these 6 study groups took Curcumin and Turmeric with anything else.

6 study groups

Study
Efficacy and safety of curcumin in patients with hand osteoarthritis: a pilot double-blinded randomised controlled trial
2025 · curcumin group · Adults over 50 years with hand osteoarthritis and hand pain or stiffness; mostly women
86.3 mg1.5 g90 days13
Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments
2021 · Curcumin with turmeric oils · 12 healthy adults
207 mg—1 day12
Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans
2019 · turmeric powder meal · healthy male participants; age not reported
400 mg—1 day—
Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans
2019 · grated fresh turmeric root meal · healthy male participants; age not reported
400 mg—1 day—
Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study
2011 · trial group · Patients with overt type 2 diabetic nephropathy; age and sex not specified
66.3 mg1.5 g60 days20
Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study
2012 · trial group · Patients with relapsing or refractory biopsy-proven lupus nephritis
66.3 mg1.5 g90 days12